Belite Bio to Participate in Four Major Investor Conferences in September

SAN DIEGO, Sept. 01, 2026 /CourierPR/ -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on treating degenerative retinal diseases, will participate in four major investor conferences in September 2026. The company will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, the 2026 Cantor Global Healthcare Conference in New York, the Morgan Stanley 24th Annual Global Healthcare Conference in New York, and the H.C. Wainwright 28th Annual Global Investment Conference also in New York. Presentations will take place on September 8, 9, 14, and 15, respectively, all starting at 8:45 AM ET, 10:55 AM ET, 7:45 AM ET, and 9:00 AM ET.

At the Wells Fargo conference, the company will conduct a fireside chat. Belite Bio will also share insights at the Cantor Global Healthcare Conference, the Morgan Stanley Global Healthcare Conference, and the H.C. Wainwright Global Investment Conference, all through fireside chats. Attendees can access the webcasts on the company's investor relations section of its website, which will remain available for 90 days after each presentation.

Belite Bio's lead candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of bisretinoid toxins in the eye. The company has already completed a successful Phase 3 trial (DRAGON) in adolescents and adults with Stargardt disease type 1 (STGD1). Tinlarebant is currently being evaluated in a Phase 2/3 trial (DRAGON II) for STGD1 and in a Phase 3 trial (PHOENIX) for subjects with geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD).